- Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
Leukemia (2017-02-22)
A Hochhaus, T Masszi, F J Giles, J P Radich, D M Ross, M T Gómez Casares, A Hellmann, J Stentoft, E Conneally, V García-Gutiérrez, N Gattermann, W Wiktor-Jedrzejczak, P D le Coutre, B Martino, S Saussele, H D Menssen, W Deng, N Krunic, V Bedoucha, G Saglio
PMID28218239
RÉSUMÉ
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR
MATÉRIAUX